# Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition

- Source: PR Newswire M&A
- Published: 2026-11-04T14:15:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/rigel-announces-oral-presentation-of-phase-1b-data-for-r289-in-patients-with-lower-risk-mds-at-the-68th-american-society-of-hematology-annual-meeting-and-exposition-302929341.html
- Canonical: https://groundlevelnews.com/story/rigel-announces-oral-presentation-of-phase-1b-data-for-r289-in-patient-90c936/

Oral presentation to feature updated data from the dose escalation and dose expansion phases of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk MDS Three poster presentations will highlight data for TAVALISSE®...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._